Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

1.

How to optimize the use of biobanks from population-based cohorts in aging research.

Berr C, Gabelle A, Fievet N, Goldberg M, Zins M, Carriere I.

Biogerontology. 2015 Jun 26. [Epub ahead of print]

PMID:
26112233
2.

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study.

Dumurgier J, Schraen S, Gabelle A, Vercruysse O, Bombois S, Laplanche JL, Peoc'h K, Sablonnière B, Kastanenka KV, Delaby C, Pasquier F, Touchon J, Hugon J, Paquet C, Lehmann S.

Alzheimers Res Ther. 2015 Jun 1;7(1):30. doi: 10.1186/s13195-015-0114-5. eCollection 2015.

3.

Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease.

Lehmann S, Delaby C, Paquet C, Gabelle A.

Clin Chem Lab Med. 2015 Jul 1;53(8):e175-7. doi: 10.1515/cclm-2014-1232. No abstract available.

PMID:
25870963
4.

Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications.

Bros P, Delatour V, Vialaret J, Lalere B, Barthelemy N, Gabelle A, Lehmann S, Hirtz C.

Clin Chem Lab Med. 2015 Feb 18. pii: /j/cclm.ahead-of-print/cclm-2014-1048/cclm-2014-1048.xml. doi: 10.1515/cclm-2014-1048. [Epub ahead of print]

PMID:
25719328
5.

[Injectable preparation of labeled leucine with the carbon 13 for a clinical research program on the Alzheimer disease: pharmaceutical control of raw materials and the finished product and stability study].

Tall ML, Lehmann S, Diouf E, Gérard C, Filali S, Gabelle A, Hirtz C, Gabert L, Sauvinet V, Pirot F, Pivot C.

Ann Pharm Fr. 2015 Jan;73(1):43-59. doi: 10.1016/j.pharma.2014.06.002. Epub 2014 Jul 11. French.

PMID:
25577016
6.

A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles.

Lehmann S, Dumurgier J, Schraen S, Wallon D, Blanc F, Magnin E, Bombois S, Bousiges O, Campion D, Cretin B, Delaby C, Hannequin D, Jung B, Hugon J, Laplanche JL, Miguet-Alfonsi C, Peoc'h K, Philippi N, Quillard-Muraine M, Sablonnière B, Touchon J, Vercruysse O, Paquet C, Pasquier F, Gabelle A.

Alzheimers Res Ther. 2014 Jun 26;6(3):38. doi: 10.1186/alzrt267. eCollection 2014.

7.

Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?

Lehmann S, Gabelle A, Paquet C.

Alzheimers Dement. 2014 Nov 15. pii: S1552-5260(14)02825-8. doi: 10.1016/j.jalz.2014.09.003. [Epub ahead of print] No abstract available.

PMID:
25457432
8.

Amyloid imaging in Alzheimer's disease: a literature review.

Saidlitz P, Voisin T, Vellas B, Payoux P, Gabelle A, Formaglio M, Delrieu J.

J Nutr Health Aging. 2014 Jul;18(7):723-40. doi: 10.1007/s12603-014-0485-5. Review.

PMID:
25226113
9.

Plasma β-amyloid 40 levels are positively associated with mortality risks in the elderly.

Gabelle A, Schraen S, Gutierrez LA, Pays C, Rouaud O, Buée L, Touchon J, Helmer C, Lambert JC, Berr C.

Alzheimers Dement. 2015 Jun;11(6):672-80. doi: 10.1016/j.jalz.2014.04.515. Epub 2014 Jul 9.

PMID:
25022539
10.

Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy.

Dauvilliers YA, Lehmann S, Jaussent I, Gabelle A.

Front Aging Neurosci. 2014 Jun 11;6:119. doi: 10.3389/fnagi.2014.00119. eCollection 2014.

11.

Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer's disease signature.

Xie J, Gabelle A, Dorey A, Garnier-Crussard A, Perret-Liaudet A, Delphin-Combe F, Bathsavanis A, Dauphinot V, Lehmann S, Mercier B, Desestret V, Roullet-Solignac I, Vighetto A, Krolak-Salmon P.

J Alzheimers Dis. 2014;41(4):1109-16. doi: 10.3233/JAD-131916.

PMID:
24762946
12.

Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder.

Lehmann S, Relano-Gines A, Resina S, Brillaud E, Casanova D, Vincent C, Hamela C, Poupeau S, Laffont M, Gabelle A, Delaby C, Belondrade M, Arnaud JD, Alvarez MT, Maurel JC, Maurel P, Crozet C.

PLoS One. 2014 Feb 14;9(2):e88797. doi: 10.1371/journal.pone.0088797. eCollection 2014.

13.

Impact of harmonization of collection tubes on Alzheimer's disease diagnosis.

Lehmann S, Schraen S, Quadrio I, Paquet C, Bombois S, Delaby C, Dorey A, Dumurgier J, Hirtz C, Krolak-Salmon P, Laplanche JL, Moreaud O, Peoc'h K, Rouaud O, Sablonnière B, Thouvenot E, Touchon J, Vercruysse O, Hugon J, Gabelle A, Pasquier F, Perret-Liaudet A.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S390-S394.e2. doi: 10.1016/j.jalz.2013.06.008. Epub 2013 Oct 23.

PMID:
24269268
14.

Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study.

Mouton-Liger F, Wallon D, Troussière AC, Yatimi R, Dumurgier J, Magnin E, de la Sayette V, Duron E, Philippi N, Beaufils E, Gabelle A, Croisile B, Robert P, Pasquier F, Hannequin D, Hugon J, Paquet C.

J Neurol. 2014 Jan;261(1):144-51. doi: 10.1007/s00415-013-7160-3. Epub 2013 Oct 27.

PMID:
24162039
15.

Development and validation of dried matrix spot sampling for the quantitative determination of amyloid β peptides in cerebrospinal fluid.

Delaby C, Gabelle A, Meynier P, Loubiere V, Vialaret J, Tiers L, Ducos J, Hirtz C, Lehmann S.

Clin Chem Lab Med. 2014 May;52(5):649-55. doi: 10.1515/cclm-2013-0611.

PMID:
24150208
16.

SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis.

Le Ber I, Camuzat A, Guerreiro R, Bouya-Ahmed K, Bras J, Nicolas G, Gabelle A, Didic M, De Septenville A, Millecamps S, Lenglet T, Latouche M, Kabashi E, Campion D, Hannequin D, Hardy J, Brice A; French Clinical and Genetic Research Network on FTD/FTD-ALS.

JAMA Neurol. 2013 Nov;70(11):1403-10. doi: 10.1001/jamaneurol.2013.3849.

17.

Biomarkers of Alzheimer's disease: the present and the future.

Lehmann S, Delaby C, Touchon J, Hirtz C, Gabelle A.

Rev Neurol (Paris). 2013 Oct;169(10):719-23. doi: 10.1016/j.neurol.2013.07.012. Epub 2013 Sep 7. Review.

PMID:
24021316
18.

Prion replication occurs in endogenous adult neural stem cells and alters their neuronal fate: involvement of endogenous neural stem cells in prion diseases.

Relaño-Ginès A, Gabelle A, Hamela C, Belondrade M, Casanova D, Mourton-Gilles C, Lehmann S, Crozet C.

PLoS Pathog. 2013;9(8):e1003485. doi: 10.1371/journal.ppat.1003485. Epub 2013 Aug 1.

19.

Exacerbated CSF abnormalities in younger patients with Alzheimer's disease.

Dumurgier J, Gabelle A, Vercruysse O, Bombois S, Laplanche JL, Peoc'h K, Schraen S, Sablonnière B, Pasquier F, Touchon J, Lehmann S, Hugon J, Paquet C.

Neurobiol Dis. 2013 Jun;54:486-91. doi: 10.1016/j.nbd.2013.01.023. Epub 2013 Feb 13.

PMID:
23416172
20.

C9orf72 repeat expansions are a rare genetic cause of parkinsonism.

Lesage S, Le Ber I, Condroyer C, Broussolle E, Gabelle A, Thobois S, Pasquier F, Mondon K, Dion PA, Rochefort D, Rouleau GA, Dürr A, Brice A; French Parkinson’s Disease Genetics Study Group.

Brain. 2013 Feb;136(Pt 2):385-91. doi: 10.1093/brain/aws357.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk